Voyager Therapeutics (VYGR) EBT (2014 - 2026)

Voyager Therapeutics (VYGR) has 13 years of EBT data on file, last reported at -$27.9 million in Q1 2026.

• For the quarter ending Q1 2026, EBT rose 9.88% year-over-year to -$27.9 million; the trailing twelve-month figure through Mar 2026 stood at -$116.5 million (down 38.7% YoY), and the FY2025 full-year result was -$119.6 million, down 85.86% from the prior year.
• EBT slipped to -$27.9 million in Q1 2026, from -$27.4 million in the prior quarter.
• In the past five years, EBT ranged from a high of $124.7 million in Q1 2023 to a low of -$33.9 million in Q4 2024.
• A 5-year average of -$7.3 million and a median of -$22.1 million in 2023 frame the typical range for EBT.
• Peak annual rise in EBT reached 685.15% in 2023, while the deepest fall reached 247.97% in 2023.
• Tracing VYGR's EBT over 5 years: stood at -$23.6 million in 2022, then soared by 342.34% to $57.2 million in 2023, then plunged by 159.25% to -$33.9 million in 2024, then increased by 19.13% to -$27.4 million in 2025, then fell by 1.85% to -$27.9 million in 2026.
• Business Quant data shows VYGR's EBT at -$27.9 million in Q1 2026, -$27.4 million in Q4 2025, and -$27.8 million in Q3 2025.